Nexentis Technologies Inc. (formerly N2OFF, Inc.) is undergoing a major strategic pivot from its agricultural clean-tech roots toward AI-driven mitochondrial drug discovery, conducted through its wholly owned subsidiary MitoCareX Bio Ltd. While the company's proprietary MITOLINE computational platform opens up a novel target space in the historically undrugged mitochondrial SLC25 carrier family, the pipeline remains in the very early preclinical stages. To fund this high-risk biotech transition, Nexentis is leveraging a secondary strategy of investing in and monetizing European solar energy assets (such as the Melz project). Although recent partial monetization deals provide near-term liquidity, the company remains a highly volatile micro-cap stock with negative earnings, substantial historical losses, and ongoing capital requirements. A 'Hold' recommendation is advised until MitoCareX Bio demonstrates concrete clinical trial progression or further solar asset realizations stabilize the balance sheet.